REPAIR, REGENERATE & RENEW: Cutting-Edge Stem Cell Research at
Tisch MS Research Center of New York
- MS affects 2.3 million people worldwide
- Over 400,000 people in the U.S. suffer from MS
- Every week, approximately 200 people are diagnosed with MS
- MS affects young adults in their prime as most are diagnosed between age 20-40
- MS affects twice as many women than men
- The cause of MS is not yet known
- Although there are some treatments that may halt progression, there is no cure for MS
- The objective of the Phase I trial is to test safety.
- Data from the Phase I trial will lead to an improved strategy for Phase II
- Positive outcomes of the trial may indicate the use of this therapy in other neurological diseases like ALS and Parkinson's Disease, cerebral palsy and spinal cord injuries.
In pre-clincal, non-human experiments of our stem cell therapy, renewal, repair and regeneration of myelin occurred in the CNS after intrathecal (via spinal fluid, not intravenous) injection.
From our preclinical models, we know that stem cells injected into the spinal fluid can have significant benefit in terms of improved neurological symptoms.
MS is characterized by brain inflammation, loss of myelin, damage to oligodendrocytes (the cells that make myelin), damage to neurons, and scar formation in the brain. As a result, nerve signals are not properly conducted, causing loss of neurological function. Stem cells are hypothesized to promote repair in MS by migrating to areas of demyelination, blocking damage-forming events, and enabling repair.Why Neural Stem Cells?
Our unique clinical trial uses adult autologous bone marrow-derived mesenchymal stem cells as a source for neural progenitors (MSC-NPs) to promote myelin repair that can potentially reverse or prevent disability in MS patients. Tisch MSRCNY is the only MS Center that has received FDA approval for a stem cell therapy using MSC-NPs for MS patients.
- Bone marrow is taken from patient's hip or sternum
- The sample is taken to the laboratory to isolate and expand the mesenthymal stem cells (MSCs)
- Neural progenitors (NPs) are derived from the MSCs to produce MSC-NPs
- MSC-NPs are injected into the patient's spinal fluid
- This process is repeated once every three months